President Donald Trump is expected to nominate Stephen Hahn as Food and Drug Administration (FDA) commissioner on Friday, according to reports citing sources familiar with the matter.
Hahn has served as chief medical executive at MD Anderson Cancer Center in Texas. He emerged as the frontrunner to lead the FDA in recent months, beating out current acting FDA chief Ned Sharpless and Harvard dermatology professor Alexa Boer Kimball.
Sharpless’s tenure as acting commissioner ends on Friday. While Hahn goes through the confirmation process, Trump is expected to name Health and Human Services (HHS) official Brett Giroir as a new acting commissioner, according to Politico. Giroir is currently HHS assistant secretary of health, a role he has held since February 2018.
The FDA has been without a permanent leader since Scott Gottlieb departed the agency in April. Sharpless, previously director of the National Cancer Institute, has headed up the FDA since then. He will return to his previous role at the National Cancer Institute once Giroir is appointed, The Washington Post reported.